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Study highlights: 
Current knowledge 
The predictors and prevalence of disturbed sleep in cirrhosis are not well known 
There is conflicting data on the association of disturbed sleep with hepatic encephalopathy 
 
What is new here 
Disturbed is very prevalent in cirrhosis, and is associated with hypolabuminemia, muscle cramps and opiate 
therapy 
Disturbed sleep is significantly associated with impaired quality of life in cirrhosis 
Disturbed sleep is associated with impaired cognitive function in cirrhosis 
Disturbed sleep is associated with derangement of several metabolic pathways including gut microbial 
metabolism 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract 
Background & Aims: Sleep disturbances are common in patients with cirrhosis, but their determinants and 
effects on health-related quality of life are not well understood. We investigated the prevalence of disturbed 
sleep in these patients, factors associated with sleep disruption, and effects on quality of life.  
 
Methods: We performed a prospective, cross-sectional study of 193 stable ambulatory patients with cirrhosis 
(154 with decompensated cirrhosis). Participants completed the Pittsburgh sleep questionnaire index (to assess 
sleep quality), the chronic liver disease questionnaire (CLDQ), muscle cramp questionnaires, and underwent 
neurocognitive testing. Actigraphy was performed in a subset of patients with normal and disturbed sleep. We 
collected serum samples from subjects with normal and disturbed sleep and performed non-targeted 
metabolomic analyses.  
 
Results: Of the study subjects, 157 (81%) had disturbed sleep, with Pittsburgh sleep questionnaire index scores 
>5. Disturbed sleep was associated with muscle cramps, daytime somnolence, and decreased quality of life, 
based on CLDQ scores. Factors independently associated with disturbed sleep in logistic regression analysis 
included hypoalbuminemia, opiate therapy, and muscle cramps. Disturbed sleep was independently associated 
with CLDQ score (correlation parameter, –36.6; 95% CI, –24 to –49; P<.001) on linear regression. Disturbed 
sleep was associated with neurocognitive impairment and with significantly delayed bedtime and decreased 
total sleep time, measured by actigraphy. Disturbed sleep was associated with metabolome signatures of 
alterations to the intestinal microbiome and lipid, arginine, and urea cycle metabolism.   
 
Conclusion: Most patients (81%) with advanced cirrhosis have disturbed sleep. This has negative effects on 
quality of life and is associated with disruptions of several metabolic pathways, including metabolism by the 
intestinal microbiota.  
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Introduction 
 
Patients with cirrhosis experience a decrease in health-related quality of life, associated with ascites, hepatic 
encephalopathy (HE), debilitation, fatigue, muscle cramps and other complications of liver disease. 1 Sleep 
disturbances have been reported to impact the quality of life in patients with cirrhosis.2 Sleep disturbances in 
patients with cirrhosis include difficulty with falling asleep, fragmented  night-time  sleep and increased 
daytime somnolence.3  
 
These symptoms are commonly attributed to the presence of HE. Reversal of the sleep-wake cycle is considered 
an early sign of HE, and is associated with impaired daytime functioning. 3 In addition, HE has been associated 
with disordered circadian cycle, melatonin profile and sleep quality in animal models and human studies.4-8 
Sleep is known to transiently worsen after transjugular intrahepatic shunting and induced hyperammonemia9,10 
In addition self-reported sleep is described to improve after lactulose initiation for minimal HE.11 On the other 
hand, the prevalence of insomnia is not related to psychometric performance in cirrhosis,12 and the severity of 
HE was not associated with insomnia.2 Sleep quality may be impaired for other reasons in cirrhosis, and 
observational studies on sleep quality indicate an increase in the prevalence of sleep disturbances in patients 
with cirrhosis, even in the in the absence of minimal or overt HE. 2,12 The association between HE and disturbed 
sleep remains unclear.   
 
A number of tools have been developed and validated to assess subjective sleep quality, including the  
Pittsburgh Sleep Quality Index (PSQI) for night time sleep and the Epworth Sleepiness Scale (ESS) for daytime 
somnolence.13,14 Sleep quality has also been objectively assessed in liver and other disease states using 
actigraphy. This utilizes an accelerometer equipped, wrist worn device that sensitively tracks periods of 
immobility reflecting duration and quality of sleep (supplemental figure 3). This allows assessment of sleep in 
the home environment and daily routine. Actigraphy measured sleep and self-reported sleep varied by health 
and sleep characteristics in young adults.15 In other studies on non-clinical samples of young and older adults, 
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there was no correlation of actigraphy measurements with PSQI measures.16 Sleep  studies in patients with 
cirrhosis using actigraphy have demonstrated delayed time to bed, increased night-time activity and fragmented 
sleep.6  It is not clear how well actigraphy derived sleep parameters would correlate with standardized sleep 
questionnaires in patients with cirrhosis.  
 
The prevalence of sleep disturbances in selected patients with cirrhosis are estimated at  48% to 55%. 3,12 
Anecdotally, the majority of patients with cirrhosis report some degree of difficulty with sleep, but the 
prevalence of sleep disorders in large academic hepatology practices is undefined. Additionally, studies on the 
correlates of disturbed sleep in cirrhosis have rarely described the impact on quality of life. 3,6,9,12,17 The aims of 
this study were to describe the prevalence of disturbed sleep in patients with cirrhosis in a large hepatology 
practice, and assess its impact on health-related quality of life. Additional aims of the study were to; i) describe 
the differences in neurocognitive function associated with disturbed sleep, ii) compare actigraphy results in 
subjectively normal and disturbed sleep, and iii) conduct an exploratory metabolomic analyses in a subset of 
patients with and without disturbed sleep. 
 
Materials and Methods 
 
Subjects 
Adults with cirrhosis seen in the hepatology outpatient clinics at Indiana University between December 2012 
and January 2014 were eligible for this prospective study, with a target enrollment of 200 subjects. The study 
was approved by the Indiana University Institutional Review Board. Cirrhosis was defined based on clinical and 
imaging (and with histological features where available).  A priori exclusion criterion was  overt HE (West 
Haven score ≥ 2) as judged clinically by investigators at the time of enrollment and study questionnaires. 
Patients attending both general hepatology and transplant hepatology clinics were invited by study personnel to 
participate in this study.  Consenting subjects completed questionnaires to assess their sleep quality, daytime 
somnolence and quality of life. Data collected included demographics, etiology, severity and complications of 
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liver disease, comorbidities,  known sleep disorders and medication use. Patients with known sleep disorders 
such as obstructive sleep apnea (OSA) or restless leg syndrome (RLS) were not excluded, but were accounted 
for in descriptive and subgroup analysis. Similarly, patients reporting active alcohol or psychoactive/sedating 
drug  use were not excluded since they represent a significant subset of patients with end stage liver disease. 
Aliquots of serum were frozen at -800C. 
  
Questionnaires and Neurocognitive testing 
 
Quality of sleep was assessed by the Pittsburg Sleep Quality Index (PSQI) was used to assess the quality of 
sleep. 13 The Epworth Sleepiness Scale was used to assess daytime somnolence or likelihood of falling asleep in 
different situations of daily living.14 The Chronic Liver Disease Questionnaire (CLDQ) was be used to assess 
the health related quality of life in subjects.18,19 Muscle cramps were recently shown to be independently 
associated with  reduced quality of life in cirrhosis. 20 Therefore, supplemental questions were included to 
assess for muscle cramps in the last 24 hours, and to describe the time of day they occurred. The Number 
Connection Test (NCT) A and B and the Inhibitory Control Test (ICT) were applied to all subjects at the time of 
completion of study questionnaires have been used to detect covert HE.21,22  (Details of questionnaire 
definitions and neurocognitive testing are described in the supplemental data)  
 
Actigraphy 
A subset of enrolled subjects, with good sleep and poor sleep, completed actigraphy. Subjects were instructed to 
wear the actigraphy wrist device (Actiwatch 2®, Philips Respironics, Andover, MA) for 2 weeks. Data were 
analyzed using the automated settings (Actiware®, Philips Respironics), with standardized reporting of time to 
sleep, time of waking, total time in bed and sleep time, sleep latency, wake time after sleep onset and  number 
of awakenings per night.  
 
Metabolomics 
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The mechanism by which sleep is disturbed in cirrhosis is not well understood. However, given the potential 
association with HE, we borrowed from recent insights into the pathogenesis of HE relating to alterations in the 
intestinal metabiome and gut-brain axis.23,24 We postulated that disturbed sleep in patients with cirrhosis may be 
associated with alterations in metabolic pathways including gut metabiome. Non-targeted metabolic profiling 
was conducted on stored serum obtained from cirrhotic patients reporting good sleep (PSQI 0-5) (n=26), and 
poor sleep (PSQI>5) (n=54). Out of 54 patients with poor sleep, 20 had mildly disturbed sleep  (PSQI 6-8) 
whereas 34 had severely disturbed sleep  (PSQI >11).  One-way ANOVA was used to compare groups and p 
<0.05 was considered significant. Random Forest  analysis was used to identify top ranking metabolites of 
importance to the classification scheme. 
 
Statistical analysis   
Descriptive analysis was performed to determine prevalence of poor sleep in the study cohort, and comparison 
of demographic and clinical variables in good and poor sleepers. In addition simple and multiple logistic 
regression for predictors of poor sleep, and linear regression for predictors of quality of life by CLDQ were 
performed. Factors associated with P < .1 were included in the multiple regression analysis. Analysis was 
performed with SPSS 21 (International Business Machines, New York). All tests were 2 tailed with a threshold 
of significance at P <.05. 
 
Results 
A total of 200 subjects were enrolled during the study period. Seven subjects were excluded from the analysis 
due to non-completion of the PSQI instrument (3), withdrawal from the study  (1), unconfirmed diagnosis of 
cirrhosis (1), alternating third work shift schedule (1) and interferon based therapy (1). Thirty-six (18.6%) of the 
193 studied subjects had PSQI ≤5 (mean 3±1) i.e. subjectively good sleep, and 157 (80.9%) had PSQI>5 (mean 
12±4) i.e. poor sleep. Eight patients did not complete all parts of the PSQI, but had a score>5 based on available 
data and were categorized as having poor sleep.  
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Demographic and clinical variables were compared in subjects reporting good vs. poor sleep (Table 1). The 
prevalence of poor sleep in subjects with Childs class A, B and C disease was 71%, 85% and 93% respectively 
(p = 0.02), and in patients with compensated and decompensated cirrhosis was 70% and 84% respectively (P = 
0.04). Muscle cramps were reported to occur in the nighttime in 38%, daytime in 2%, and both day and 
nighttime in 56% of subjects (4% did not report the time of cramps). Eighteen subjects reported OSA (3 also 
reported RLS), and OSA was more frequent in patients with poor sleep (table 1). A small number (7) of  
subjects reported a history of RLS (6 with poor sleep and 1 with good sleep), which limited meaningful analysis 
of RLS as a covariate. Patients with poor sleep had increased daytime somnolence as rated by the ESS, and 
worse quality of life as indicated by a lower mean CLDQ score (table 1).     
 
Determinants of poor sleep and quality of life 
Simple and multiple logistic regression analysis for the determinants of poor sleep are described in table 2. 
Muscle cramps, hypoalbuminemia and opiate therapy were independently associated with poor sleep. Poor 
sleep was associated with lower CLDQ on multiple linear regression (correlation parameter -36.6; 95% CI; -24 
to -49; P <.001), as were muscle cramps and HE (table 3). Poor sleep remained an independent predictor of 
lower CLDQ when analyzing the 154 patients with decompensated cirrhosis (correlation parameter -38.3, 
95%CI from -23 to –53.7), and the 72 patients not reporting OSA, RLS, cramps or opiate use (correlation 
parameter -35.4; 95% CI, -21.2 to -49.6; P <.001).  
 
Comparisons of neurocognitive tests in patients with good and poor sleep are described in supplemental table 5. 
Actigraphy was completed in  11 subjects with good sleep and 10 subjects with disturbed sleep over a median 
interval of 14 days (interquartile range 12 to 14 days)  (table 4). Disturbed sleep was associated with a delayed 
bed time, and shorter total sleep time, but no differences in sleep latency, sleep efficiency or number of 
awakenings. There was no correlation between sleep efficiency or latency by actigraphy and respective 
parameters by PSQI.  
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Categorization of poor sleep according to PSQI 
A wide distribution of PSQI and CLDQ scores in this large cohort presented an opportunity to analyze 
categories of sleep disturbance by PSQI. The 8 subjects who had not completed all sub-components of the PSQI 
were excluded in this post-hoc analysis.  Sleep in the remaining 185 subjects was categorized as normal (PSQI 
0-5) in 36 (20%), and the degree of sleep disturbance as mild (PSQI 6-8) in 42 (23%), moderate (PSQI 9-11) in 
35 (19%) and severe (PSQI>11) in 72 (36%). Daytime somnolence was increased (ESS >9) in 22%, 40%, 51% 
and 61% of subjects with normal, mild, moderate and severe sleep disturbance, respectively ( P =0.002). 
Worsening sleep category was significantly associated with progressive decrease in CLDQ (figure 1). This 
association held after excluding subjects with OSA, RLS, muscle cramps or opiate use (supplemental figure 4).  
 
Differences in neurocognitive testing between mild and severe sleep disturbance became more pronounced 
when comparing subjects without  OSA, RLS, muscle cramps or opiate therapy (supplemental table 6). Notably 
a high proportion of subjects, even those with good sleep had >5 incorrect lure responses on the ICT, suggesting 
that there was likely a high prevalence of covert HE in the study group.  
 
Metabolomics 
Metabolomic analysis was performed in 80 subjects, excluding OSA, RLS and opiate therapy (supplemental 
table 7). The biochemical profiling identified 508 serum metabolites, and of these, 45 metabolites differed 
significantly between patients with no and mild sleep disturbance, 54 metabolites differed between patients with 
no and severe sleep disturbance, and 45 metabolites differed between those with mild and severe sleep 
disturbance.  Random Forest classification identified metabolites important to the classification scheme that 
spanned several different metabolic pathways (top  biochemicals are shown in Figure 2).  Analysis of the top 
biochemicals that were altered to the greatest degree (p<0.009) among the 3 groups identified several 
metabolites included within the Random Forest importance plot such as gamma-glutamyl amino acids, 
taurocholate, tyrosine, 10-hydroxyoctadecanoic acid, select lysolipids, and citrulline.  Changes in biochemicals 
reflective of altered gut microbial metabolism, lipid metabolism, and arginine metabolism and the urea cycle 
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were particularly pronounced.  Further examination of the altered gut microbial metabolites revealed changes in 
several amino acid-derived (pipecolate, 3-(4-hydroxyphenyl) lactate, 3-(4-hydroxyphenyl) propionate, 
indoleacetate and indoleacetylglutamine), and lipid-derived (3-dehydrocarnitine and 10-hydroxyoctadecanoic 
acid) metabolites in individuals with mild and severe sleep disturbance.  Despite elevations in the lipolysis 
marker glycerol in both the poor sleep and very poor sleep groups, circulating levels of free fatty acids were 
only substantially altered in the poor sleep group. Consistent reductions in choline-containing lysolipids were 
only observed in the very poor sleep group. These findings highlight a role for changes in lipid handling and 
phospholipid metabolism in altered sleep in patients with cirrhosis. Consistent elevations in several gamma-
glutamyl amino acids, suggestive of greater activity of the gamma-glutamyltranspeptidase (GGT) enzyme 
associated with the gamma-glutamyl cycle, were observed in both groups of patients with poor sleep. This 
suggests that changes in activity of the gamma-glutamyl cycle, possibly through alterations in glutathione 
metabolism and oxidative stress, may play a role in underlying pathologies related to perturbations in sleep 
patterns in patients with cirrhosis. Interestingly, several biochemicals produced when gut flora metabolize the 
food additive sodium benzoate (3-hydroxyhippurate, catechol sulfate and 4-methylcatechol sulfate) were 
significantly lower in individuals with mild and severe sleep disturbance.  
 
Only 2 metabolites were significantly associated with both muscle cramps and poor sleep (supplemental table 
8). These were xylulose which is associated with pentose metabolism and oxidized cys-glycine which is 
associated with glutathione metabolism. While altered liver function is expected in all patients included in this 
study regardless of sleep status, additional changes in biochemical markers of hepatic function were observed 
when comparing the poor sleep and/or very poor sleep groups to the good sleep group. Accumulation of select 
taurine-conjugated bile acids and was noted in both groups of patients with poor sleep, suggestive of decreased 
hepatic function in cirrhotics with perturbed sleep patterns Notably, poor and very poor sleep were associated 
with significantly higher Childs Pugh score, though not MELD, (supplemental table 7), raising concern for 
potential confounding of the metabolomic study results by the severity of liver disease. We performed 
additional analysis comparing the metabolites associated with poor and very poor sleep in subgroups stratified 
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by Childs Pugh Class (supplemental results). The majority of metabolites remained significantly different in 
subjects with poor and very poor sleep compared with subjects with good sleep, remained significantly different 
when compared in subjects within at least one Childs Pugh Class.  
 
Discussion 
 
 
This study highlights the high prevalence of disturbed sleep in patients with cirrhosis (81%), relative to previous 
reports citing rates of 48 to 55%.3,12  This may be explained by the less stringent exclusion criteria used for 
enrollment (allowing patients with sleep disorders and patients using alcohol, sedatives and opiates), and the 
more advanced liver disease since the study was performed at a high volume liver transplant center. The size of 
the cohort allowed for a robust analysis of the determinants of disturbed sleep in cirrhosis. Disturbed sleep was 
independently associated with muscle cramps, a common problem in patients with cirrhosis that has been 
recently shown to  independently and negatively impact quality of life.20  There is little data at present 
describing the predictors of poor sleep in cirrhosis. In this cohort hypoalbuminemia and opiate therapy were 
independent determinants of poor sleep. While opiate use may be a surrogate marker of chronic pain, which 
may be the underlying factor impairing sleep quality, this data only highlights the association with disturbed 
sleep, but not the reason for it. Notably patients with known sleep disorders such as OSA and RLS, or those 
using opiates, who would have been excluded in prior studies,  were included here, lending broader 
applicability of the descriptive findings. The associations of poor sleep with quality of life persisted after 
sensitivity analysis excluding patients with these factors. These data suggest that disturbed sleep in cirrhosis 
may be multi-factorial in etiology, and that studies on sleep in cirrhosis require accurate phenotyping of not 
only other sleep disturbances, but also of muscle cramps, chronic pain and opiate therapy.  
 
An important finding of this study, was that disturbed sleep was a powerful and independent predictor of 
decreased quality of life, even after excluding potential confounders, with a narrow range  of the correlation 
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parameter (-35.4 to -38.8) in multiple models. Therefore disturbed sleep represents an important unmet need in 
patients with cirrhosis. 
 
At present the relationship of disturbed sleep and HE is unclear.2,12,25  Measures of neurocognitive function in 
subjects with poor sleep were notably worse than those with good sleep, particularly after excluding subjects 
with muscle cramps, opiate therapy, OSA or RLS. This suggests that there is an association of disturbed sleep 
with neurocognitive dysfunction, which may only be apparent after excluding subjects with poor sleep related to 
other sleep disorders or chronic pain/opiate therapy. Additional studies on sleep disturbances in patients with 
better characterization of covert HE are warranted to better understand that relationship. 
 
The subjective assessments of sleep quality were compared in a subset of patients with objective measures of 
sleep using actigraphy. The finding of delayed sleep onset corroborates previous findings,2,6,12 which 
interestingly presents a pattern of disordered sleep in cirrhosis akin to delayed phase sleep disturbance.26 There 
were  no differences in sleep efficiency, latency or number of awakenings, which have already been shown to 
be impaired in patients with cirrhosis compared to healthy controls.6,12,27 However,  this study was intended to 
assess correlation of objective sleep parameters in disturbed sleep in patients with cirrhosis, and lacked a  
comparison group of healthy individuals without cirrhosis.  
 
The finding of meaningful differences between the categories of disturbed sleep in relation to quality of life, 
daytime sleepiness and neurocognitive function, particularly for mild (PSQI=6-8) vs. severe (PSQ>11) 
disturbed sleep, was important. Clinical correlates have been described for similar categories of PSQI and 
disturbed sleep in blindness.28 Additionally a decrease in overall PSQI, rather than attaining a score ≤5, has 
been used and shown to correlate with therapeutic responses for disturbed sleep with a variety of associated 
conditions and interventions. 29-31 The present data suggests that categorizing the severity of sleep disturbance 
using PSQI has relevant clinical correlates in patients with cirrhosis. If confirmed, this could inform the design 
of studies on the pathogenesis and therapeutic endpoints of disturbed sleep in cirrhosis.   
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Finally, the novel metabolomic analysis suggests that cirrhotic patients with disturbed sleep (excluding those 
with OSA, RLS and opiate therapy) have a distinct serum metabolomic signature reflecting derangement of 
several metabolic pathways including gut microbial metabolism. It is not possible to establish a cause and effect 
association based on this data. However, these potential associations build on the growing evidence linking 
altered gut microbiota with disease phenotype and complications of cirrhosis, including HE.23,24 The reported 
impact of circadian dysregulation on altered gut microbiome and increased intestinal permeability lends further 
credence to the postulated association.32 The limited overlap of the significantly associated metabolites in poor 
sleep and muscle cramps suggests that the results of the metabolomics analysis were not significantly affected 
by inclusion of subjects with muscle cramps. While limited by small sample size, the metabolomics re-analysis 
stratified by Childs Pugh Class suggests that the observed differences in metabolites associated with disturbed 
sleep were not attributed to the severity of liver disease.  Additional study is needed to validate the 
metabolomics findings in a separate cohort with minimal potential confounding from severity of liver disease 
and other sleep disorders. Nevertheless, this data highlights the need to describe the microbiome characteristics 
and gut permeability associated with disturbed sleep, and this may represent a novel therapeutic approach in 
selected patients. 
 
The study has a number of limitations. It was performed at a large transplant center, consequently the subjects 
may represent a select group of cirrhotics with very advanced liver disease, hence the results may not reflect 
findings in patients with compensated cirrhosis. Few subjects reported normal sleep and the study lacked a 
normal control group, though the aim was not to compare cirrhotics to healthy individuals. The study did not 
track the number of patients refusing to participate or reasons for refusal. It did not screen for undiagnosed 
obstructive sleep apnea. The study also lacks data on circadian rhythm, including the diurnal preferences of 
subjects, and information of alterations in melatonin metabolism, although studies on association of endogenous 
melatonin metabolism and disturbed sleep in cirrhosis have been inconclusive and do not fully explain disturbed 
sleep in this population.25,26,33 The study was based on a single assessment and did not define the acuity or 
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chronicity of disturbed sleep. Finally, the study design does not rigorously define the presence of covert hepatic 
encephalopathy, but supports an association with disturbed sleep which warrants further study.   
 
In summary, we describe a high prevalence of disturbed sleep in patients with cirrhosis at a large transplant 
center. Disturbed sleep was predicted by muscle cramps, itself an important though poorly understood 
complication of end-stage liver disease. Disturbed sleep in this population appears to be multi-factorial in 
etiology, and may be associated with neurocognitive dysfunction. Disturbed sleep is strongly associated with 
decreased quality of life, and its' severity may be meaningfully categorized based on PSQI. Further studies to 
elucidate the pathogenesis and therapies for disturbed sleep in patients with cirrhosis are needed in the face of 
this significant and unmet need.  
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Figures legend 
Figure 1. A box plot describing Chronic Liver Disease Quality of life questionnaire (CLDQ) scores (median 
(bold horizontal line), interquartile range (box), and range (whiskers)) in subjects grouped according to category 
of sleep disturbance, including; normal, mild, moderate  and severe. Comparisons of CLDQ between all 
categories were statistically significant, with the exception of mild versus moderate sleep disturbance.  
 
 
Figure 2. The Random Forest classification and biochemical importance plot listing the metabolites in order of 
degree of alteration between patients with no and any sleep disturbance (2A), and between patients with no, 
mild and severe sleep disturbance (2B). 
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Tables 
 
Table 1. Demographic and clinical variables in the study cohort (N=193), comparing subjects 
with good and poor sleep. Data are reported as mean ± standard deviation or percentages.  
 Good sleepers 
(n=36) 
Poor sleeper 
(n=157) 
P  
Age (years) 59±8 57±10 .4 
Gender (male) 67% 56% .2 
Race 
White 
Black 
Hispanic 
Other 
83% 
11% 
None 
6% 
92% 
5% 
2% 
1% 
.16 
Etiology of liver disease 
Viral hepatitis 
Alcohol 
Non-alcoholic fatty liver disease 
31% 
14% 
33% 
41% 
24% 
29% 
.3 
.2 
.6 
BMI(kg/m
2
) 30.6±7.7 31±6.6 .4 
Serum albumin (g/dL) 3.8±0.4 3.5±0.6 .002 
MELD 11.7±4.7 12.7±5.3 .3 
History of overt hepatic encephalopathy 34% 55% .03 
History of ascites 40% 48% .8 
Childs Pugh score 6.4 ± 1.7 7.7 ± 2.1 .001 
Childs class 
A 
B 
C 
58% 
36% 
6% 
34% 
49% 
17% 
.02 
Hepatocellular carcinoma 11% 10% .9 
In evaluation or listed for liver transplantation 44% 56% .3 
Transjugular intrahepatic portosystemic shunt None 4% .2 
Reported muscle cramps in last 24 hours 26% 52% .005 
Obstructive sleep apnea 11% 9% .7 
Prescription opiate therapy 11% 36% .003 
Benzodiazepine therapy None 17% .009 
Epworth Sleepiness scale 
Normal (0-9) 
Borderline daytime sleepiness (10-15)  
Abnormal daytime sleepiness (16-24) 
78% 
11% 
11% 
47% 
22% 
31% 
.004 
Chronic Liver Disease Quality of life (CLDQ) 169±27 118±35 <.001 
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Table 2. A summary of simple and multiple logistic regression analysis for the determinants of 
poor sleep as defined by a Pittsburgh Sleep Quality Index (PSQI) score >5. 
*Logistic regression analysis for predictors of poor sleep ( PSQI >5) 
Simple Multiple 
Variable Odds 
ratio 
95% CI P    Odds 
ratio 
95% CI P  
Serum albumin (g/dL) 0.37 0.2– 0.7 <.001  0.4 0.2 – 0.8 .01 
Prescription opiate 
therapy 
4.6 1.5 – 13.5 .006  5 1.4 – 17.7 .01 
Muscle cramps 6.2 2.3 – 16.7 <.001  5.2 1.8 – 14.6 .002 
Hepatic encephalopathy 2.3 1.1 – 5 .03     
 
*Factors not predictive of poor sleep on simple logistic regression were; Age, gender, race,  body 
mass index,  bilirubin (mg/dL),  creatinine (mg/dL),  INR, ammonia (mg/dL),  obstructive sleep 
apnea,  etiology of liver disease category (viral hepatitis, alcoholic, fatty liver, cryptogenic, 
cholestatic or autoimmune hepatitis). 
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Table 3. A summary of the simple and multiple linear regression analysis for the predictors of 
quality life as determined by Chronic Liver Disease Quality of life questionnaire (CLDQ). 
Results describe the correlation parameter (B), its 95% confidence interval, and the associated p-
value. 
*Linear regression analysis for predictors of quality of life by CLDQ 
 Simple regression Multiple regression 
Variable B 
(correlation 
parameter) 
95% CI P  B 
(correlation 
parameter) 
95% CI P  
Poor sleep (PSQI>5) -50.6 -38.5 _-62.7  <.001 -36.6 -24  _ -49 <.001 
Prescription opiate therapy -22.8 -11.2 _-34.2 <.001 -11.2 -1.4 _ -21.1 .03 
Muscle cramps -31.6 -21.4 _ -42  <.001 -18.8 -9.5  _ -28.1 <.001 
Hepatic encephalopathy -25.2 -14.8_-35.7 <.001 -16.7 -7.7 _ -25.7 <.001 
Ascites -13.6 -2.7_-24.5 .01    
Age 0.56 -0.03_1.15 .06    
Gender (male) 11.1 -0.02 _ 22.2 .05    
Creatinine (mg/dL) 2.7 -0.2 _ 5.6 .07    
Albumin (g/dL) 17.4 8.7 _ 26.1 <.001    
Obstructive sleep apnea -17 -1.8 _ 35.9  .08 -17.7 -1.9 _ 33.5 .03 
*Factors not predictive of CLDQ  on simple logistic regression were; race (Caucasian, black or 
Hispanic),  body mass index,  bilirubin,  INR, albumin, ammonia,  etiology of liver disease 
category (viral hepatitis, alcoholic, fatty liver, cryptogenic, cholestatic or autoimmune hepatitis).  
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Table 4. Actigraphy results in subjects with good and poor sleep. Values are described as mean 
values with standard deviation 
 Good sleep 
(n=11) 
Poor sleep 
(n=10) 
P  
Bed time (hour:minutes PM) 9:10± 2:50 10:17±3:35 .02 
Get up time (hour:minutes AM) 7:41±1:45 7:42±1:09 .5 
Time in bed (minutes) 558 ± 117 499 ± 122 .04 
Total sleep time (min) 465 ± 77 423 ± 129 .04 
Sleep onset latency (min) 19±13 17±11 .7 
Sleep efficiency (%) 84 ± 5 84 ± 7 .8 
Waking after sleep onset (min) 62±33 48±22 .16 
Number of awakenings 25±8 25±14 .9 
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Supplemental data 
 
 
Supplemental methods: Questionnaires 
 
The Pittsburg Sleep Quality Index (PSQI) comprises 7 components; subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep disturbances, sleep medication, and daytime dysfunction (range 0 
to 21). Sleep is accordingly categorized as good (0 - 5) or poor (6 - 21). 13 The Epworth Sleepiness Scale was 
used to assess daytime somnolence or likelihood of falling asleep in different situations of daily living (range 0 
to 24).  The results are categorized as normal (0 - 9), borderline (10 - 15) and abnormal (16-24). 14 The Chronic 
Liver Disease Questionnaire (CLDQ) was be used to assess the health related quality of life in subjects. It has 
been validated to assess quality of life in patients with liver disease and cirrhosis, regardless of disease etiology 
and stage.18,19 NCT-A (>30 seconds) and NCT-B (>100 seconds) are associated with a sensitivity of 77% and 
87% for detecting grade 1 hepatic encephalopathy, respectively.21 More than 5 incorrect lure responses on ICT 
has been shown to identify covert HE with 90% sensitivity and specificity. 22 The ICT component results 
between groups as categorical  (>5 incorrect lure responses) and as continuous variables (lure and target 
response rates). 
 
Supplemental results: To test the potential for confounding by the severity of liver disease on the results of the 
metabolomic analysis, we performed additional analysis. The metabolites associated with poor and very poor 
sleep in the metabolomic study were compared in the same subjects stratified by Childs Pugh Class. this 
resulted in small groups, such that differences in the identified metabolites could lose statistical significance. 
We found that of the 11 metabolites that were significantly higher in cirrhotics with poor or very poor sleep vs. 
good sleep, 8 remained significantly higher in patients with disturbed sleep within at least one Childs Pugh 
Class category (phenylalanine and tyrosine (phenylalanine and tyrosine metabolsim, amino acid super 
pathway), gamma-glutamylphenylalanine and gamma-glutamyltyrosine (gamma-glutamyl amino acid 
metabolism, peptide super pathway), xylitol and sorbitol (pentose metabolism, carbohydrate super pathway), 
pregnenolone sulfate (steroid metabolism, lipid super pathway) and taurocholate (primary bile acid metabolism, 
lipid super pathway) ). One metabolite was associated with a statistical trend for being higher in poor sleepers 
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within at least one Childs Pugh Class group (ornithine (urea cycle metabolism, amino acid super pathway). The 
2 metabolites that were lower in the subjects with poor and very poor sleep compared with good sleep, were 
also significantly lower within at least one Childs Pugh Class category (3-hydroxyhippurate and catechol sulfate 
(benzoate metabolism sub-pathway, xenobiotic super pathway)). While limited, these findings suggest that the 
observed differences in metabolites associated with disturbed sleep could not be attributed to the severity of 
liver disease. 
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Supplemental Figures legend  
 
Figure 3-A  Actiwatch 2®, Phillips Healthcare (Andover MA) actigraphy wrist device, and a sample 5 day data 
recording (3-B). 
 
 
Figure 4. A box plot describing CLDQ (median (bold horizontal line), interquartile range (box), and range 
(whiskers)) in 69 subjects without obstructive sleep apnea, restless leg syndrome, muscle cramps or opiate 
therapy, and grouped according to sleep disturbance categories of normal (PSQI 0-5), mild (PSQI 6-8), 
moderate (PSQI 9-11) and severe (PSQI>11). Analysis of variance was significant, P <10-5. Comparisons of 
CLDQ between all categories were statistically significant, with the exception of mild versus moderate sleep 
disturbance. Daytime somnolence was increased in 24%, 13%, 38% and 53%, respectively, P =.07 
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Supplemental Tables 
 
Table 5. A comparison of venous ammonia levels and neuropsychometric tests (number connection tests and 
Inhibitory control test) in subjects with good and poor sleep. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: OSA obstructive sleep apnea, RLS restless leg syndrome. 
  
 
All Subjects  
 
Good sleepers 
(PSQI≤5) 
(n=36) 
Poor sleepers 
(PSQI>5) 
(n=157) 
P 
Ammonia (µg/dL) 60±40 61±39 .6 
Number connection test:  
A time (seconds) 
A >30 seconds (%) 
B time (seconds) 
B >100 seconds (%) 
38±19 
54 
83±55 
17 
41±16 
73 
97±59 
37 
.14 
.03 
.08 
.02 
Inhibitory control test  
More than 5 incorrect lure 
responses (%) 
Response to lures (%) 
Response to targets (%) 
85 
38±26 
92±16 
88 
44±28 
87±14 
.7 
.3 
.01 
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Table 6. A comparison of venous ammonia levels and neuropsychometric tests (number connection tests and 
Inhibitory control test), in all subjects with mild (PSQI range 6-8) and severe (PSQI>11) sleep disturbance, and 
in subjects without obstructive sleep apnea, restless legs syndrome, muscle cramps or opiate therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: OSA obstructive sleep apnea, RLS restless leg syndrome. 
 
 
 
All Subjects  Excluding subjects with OSA, RLS, 
muscle cramps,  or opiate therapy 
 
Mild sleep 
disturbance 
(PSQI=6-8) 
(n=42) 
Severe 
sleep 
disturbance 
(PSQI>11) 
(n=72) 
P  Mild sleep 
disturbance 
(PSQI=6-8) 
(n=17) 
Severe 
sleep 
disturbance 
(PSQI>11) 
(n=16) 
P  
Ammonia (µg/dL) 57±33 63±43 .5 64±43 53±26 .4 
Number connection test:  
A time (seconds) 
A >30 seconds (%) 
B time (seconds) 
B >100 seconds (%) 
41±18 
63 
90±63 
22 
40±15 
75 
98±55 
41 
.8 
.2 
.5 
.04 
36±11 
53 
71±24 
12 
39±10 
93 
102±49 
47 
.5 
.01 
.02 
.03 
Inhibitory control test  
More than 5 incorrect 
lure responses (%) 
Response to lures (%) 
Response to targets (%) 
82 
46±32 
88±14 
89 
41±25 
87±15 
.3 
.4 
.5 
82 
41±29 
89±17 
100 
33±15 
88±15 
.098 
.3 
.7 
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Table 7. Demographic and clinical variables in the metabolomics study cohort (N=80), comparing subjects with 
good and poor sleep. Data are reported as mean ± standard deviation or percentages. These excluded patients 
with obstructive sleep apnea, opiate or sedative use and categorized according to Pittsburgh Sleep Quality Index 
(PSQI). 
 Good sleepers 
(PSQI 0-5) 
(n=26) 
Mild sleep 
disturbance 
(PSQI 6-8) 
(n=20) 
Severe 
sleep 
disturbance 
(PSQI >11) 
(n=34) 
P  
Age (years) 58±8 58±9 59±9 .9 
Gender (male) 65% 65% 59% .8 
Race 
White 
Black 
Hispanic 
Other 
81% 
11% 
None 
8% 
95% 
None 
5% 
None 
94% 
3% 
3% 
none 
.2 
Etiology of liver disease 
Viral hepatitis 
Alcohol 
Non-alcoholic fatty liver disease 
38% 
19% 
31% 
60% 
25% 
20% 
38% 
29% 
32% 
.2 
.7 
.6 
Body mass index (kg/m2) 30±8 30±5 32±7 .4 
Serum albumin (g/dL) 3.7±0.6 3.3±0.6 3.4±0.6 .02 
MELD 11.5±4.8 12.8±5.6 13.6±5.1 .4 
Ammonia (µg/dL) 61±44 61±41 68±40 .8 
History of overt hepatic encephalopathy 38% 60% 68% .07 
History of ascites 42% 40% 68% .06 
Childs Pugh score 6.6±1.7 8±2.4 8.1±2.2 .03 
Childs class 
A 
B 
C 
58% 
34% 
8% 
32% 
47% 
21% 
32% 
44% 
24% 
.2 
In evaluation or listed for liver 
transplantation 46% 75% 68% .2 
Transjugular intrahepatic portosystemic 
shunt None 10% 6% .3 
Reported muscle cramps in last 24 hours 20% 40% 50% .06 
Epworth Sleepiness scale 
Normal (0-9) 
Borderline daytime sleepiness (10-15)  
Abnormal daytime sleepiness (16-24) 
73% 
15% 
12% 
65% 
10% 
25% 
46% 
24% 
30% 
.2 
Chronic Liver Disease Quality of life 
(CLDQ) 169±22 145±32 112±30 <.001 
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Table 8.  A summary of the ratio of metabolite levels in patients with and without muscle cramps. The 
metabolites that were significantly higher (ratio >1) or lower (ratio<1) in subjects with vs. without muscle 
cramps are shown, and are preceded by their associated metabolic super and sub pathway. The same metabolite 
ratios in subjects with poor vs. good sleep, when significantly different, are also shown for comparison. 
Super Pathway Sub Pathway Metabolite Name Metabolite ratio 
in subjects with 
vs. without 
cramps 
Metabolite 
ratio in 
subjects with 
poor vs. good 
sleep (when 
significantly 
different) 
Metabolites that were significantly higher in subjects with muscle cramps   
Carbohydrate Pentose Metabolism xylulose 1.38 1.31 
Lipid 
Medium Chain Fatty 
Acid pelargonate (9:0) 1.14   
Lysoplasmalogen 
1-(1-enyl-palmitoyl)-GPE (P-
16:0) 1.27   
1-(1-enyl-oleoyl)-GPE (P-
18:1) 1.24   
Xenobiotics Drug O-desmethylvenlafaxine 4.71   
Metabolites that were significantly lower in subjects with muscle cramps 
  
Amino Acid 
Tryptophan 
Metabolism serotonin .70   
Leucine, Isoleucine 
and Valine 
Metabolism 
3-methyl-2-oxobutyrate .84   
Glutathione 
Metabolism cys-gly, oxidized .69 .75 
Peptide Fibrinogen Cleavage Peptide ADpSGEGDFXAEGGGVR .63   
Lipid 
Ketone Bodies acetoacetate .57   
Secondary Bile Acid 
Metabolism 
glycodeoxycholate .41   
glycolithocholate sulfate .48   
Xenobiotics 
Benzoate 
Metabolism catechol sulfate .70   
Food 
Component/Plant 
ferulic acid 4-sulfate .55   
N-(2-furoyl)glycine .73   
  
  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
